Insider Sean McAuliffe plans 914-share Taysha (NASDAQ: TSHA) stock sale
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Taysha Gene Therapies insider Sean McAuliffe has filed to sell additional company stock. The notice covers 914 shares of common stock, to be sold through Maxim Group LLC on or around February 4, 2026 on Nasdaq, with an aggregate market value of $4,314.08. The filing states that 273,919,373 shares of common stock were outstanding.
The 914 shares come from a restricted stock unit award acquired on February 3, 2026, which vested and was settled in stock as compensation for continued employment. In the past three months, McAuliffe also sold 36,071 shares for $171,337.25 and 10,894 shares for $50,221.34.
Positive
- None.
Negative
- None.
FAQ
What does the latest Form 144 filing for TSHA disclose?
The filing shows Sean McAuliffe plans to sell 914 shares of Taysha Gene Therapies common stock. The planned sale, via Maxim Group LLC on Nasdaq, has an aggregate market value of $4,314.08 based on the price used in the notice.
What prior TSHA stock sales by Sean McAuliffe are disclosed?
The document lists two prior sales in the past three months: 36,071 shares of common stock sold on January 23, 2026 for $171,337.25, and 10,894 shares sold on January 26, 2026 for $50,221.34 in gross proceeds.